iCAD Announces Appointment of Two Vice Presidents to Lead Cancer Detection Sales and Marketing Teams

NASHUA, N.H., Sept. 10, 2015 /PRNewswire/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the appointments of Rodney Hawkins as Vice President of Marketing and Kathleen Kelly as Vice President of Sales for the Company's Cancer Detection business.

"Mr. Hawkins brings to the iCAD team two decades of marketing experience and a solid record of delivering significant growth in his past roles at Nuance Communications, Amicas, Inc. and GE Healthcare.  His extensive experience driving product roadmaps and go-to-market strategies will be an important asset to our team," said Stacey Stevens, Senior Vice President, Marketing and Strategy at iCAD.

"Ms. Kelly's extensive sales experience has driven significant growth in her previous roles at VuCOMP and Aurora Imaging Technology," said Ken Ferry, CEO of iCAD. "She brings over twenty years of experience in women's healthcare and diagnostic imaging to the sales team."

"We are delighted to introduce these two outstanding industry professionals to the iCAD team, especially as we work to maximize our commercial capabilities in our cancer detection business," Mr. Ferry added. "Their leadership will help us build marketing and sales capabilities to support new levels of performance as we increase our focus on and investments in cancer detection technology to address the significant market opportunity ahead. This includes the launch of our 3D breast density and 3D cancer detection software products."

iCAD also recently announced the launch of the iReveal® breast density module as the latest addition to the Company's PowerLook Advanced Mammography Platform (AMP)®, which is designed to deliver automated, rapid and reproducible assessments of breast density to help identify patients that may experience reduced sensitivity to digital mammography due to dense breast tissue. In addition, iCAD has completed a clinical reader study in support of a European regulatory submission for the 3D Cancer Detection software and plans to launch this new product in the European Union at the Journees Francaises de Radiologie (JFR) meeting in Paris in October. 

About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while enhancing patient care. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit www.icadmed.com or www.xoftinc.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company's ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "will", "continue", "anticipate", "likely", "seek", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.

Contact:
For iCAD investor relations:
The Ruth Group
Zack Kubow, 646-536-7030
[email protected]

or

For iCAD media inquiries:
Berry & Company Public Relations, LLC
Lynn Granito, 212-253-8881
[email protected]

SOURCE iCAD, Inc.